Loading patent…
AssigneesRegeneron Pharmaceuticals, Inc., Sanofi Biotechnology
InventorsChieh-I Chen, Medha R. Sasane, Denise P. Bury-Maynard
Estimating the term…
The present disclosure provides methods of treating or inhibiting cancer pain in a patient in need thereof, including selecting a patient with cancer, and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor. The present disclosure also provides methods of reducing analgesic use in a patient in need thereof, including selecting a patient with cancer, and administering to the patient a therapeutically effective amount of a PD-1 inhibitor, wherein the patient is being treated with background analgesic therapy prior to administration of the PD-1 inhibitor. In some embodiments, the disclosed methods concurrently lead to tumor regression, pain reduction, and reduced use of analgesic therapy.
A method of treating or inhibiting cancer pain, comprising:
22-24. (canceled)
(canceled)
A kit comprising a programmed death 1 (PD-1) inhibitor in combination with written instructions for use of a therapeutically effective amount of the PD-1 inhibitor for treating or inhibiting cancer pain in a patient with cancer, wherein the PD-1 inhibitor is an anti-PD-1 antibody or antigen-binding fragment thereof that comprises a heavy chain variable region (HCVR) comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) and a light chain variable region (LCVR) comprising three light chain CDRs (LCDR1, LCDR2 and LCDR3), wherein:
A method of reducing use of analgesic therapy by a cancer patient, comprising:
58-60. (canceled)
Dependencies are inferred from the claim text.